Cardiovascular disease is driven by early molecular changes in the vasculature and myocardium that often precede clinical manifestation, making protein-level analysis important for risk stratification and intervention. Proteomics provides scalable access to circulating and tissue-derived molecular readouts that reflect inflammation, endothelial dysfunction, lipid metabolism, extracellular matrix remodeling, and myocardial stress. Plasma profiling in cardiovascular cohorts can identify biomarkers associated with disease risk, diagnosis, prognosis, and therapeutic response, while cardiac and vascular tissue proteomics can define mechanisms of atherosclerosis, remodeling, heart failure, and injury. These studies can also be integrated with clinical metadata and complementary omics layers to refine molecular phenotypes and distinguish biologically relevant subgroups. Together, proteomics supports biomarker discovery, target identification, and mechanistic cardiovascular research.
Typical study designs
- Plasma profiling in cardiovascular-disease cohorts
- Cardiac and vascular tissue proteomics
- Early-risk and prognostic marker discovery
- Atherosclerosis and heart-failure mechanism studies
- Multi-omic integration of cardiovascular phenotypes
Selected cardiovascular diseases work
- Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease
- Immobility-associated thromboprotection is conserved across mammalian species from bear to human
- Sequential defects in cardiac lineage commitment and maturation cause hypoplastic left heart syndrome
- Aggrecan: a new biomarker for acute type A aortic dissection
Let's plan your study
Every study that is executed incorrectly consumes valuable sample material, and, more importantly, wastes time and manpower. In our fast-paced scientific environment, these resources cannot be recovered.